Complement C8, Human

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Toxicity: Standard Handling (A)

Native, human C8 complement component. Glycoprotein composed of three non-identical subunits of M.W. 64 kDa (α), 64 kDa (β), and 22 kDa (γ). Present in normal human serum at 55 µg/ml. On activation of complement via either the classical or alternative pathway, C5 is cleaved into C5a and C5b fragments. The nascent C5b fragment binds to C6, C7, and C8 resulting in formation of the C5b-8 complex on target surfaces. Each membrane-bound, hydrophobic C5b-8 complex combines with three to six C9 molecules to complete the assembly of the lytic C5b-9 complement membrane attack complex (MAC).

Steckel, E.W., et al. 1980. J. Biol. Chem. 255, 11997.
Petersen, B.H., et al. 1976. J. Clin. Invest. 57, 283.

Please refer to vial label for lot-specific concentration.

In PBS, pH 7.2.

Following initial thaw, aliquot and freeze (-70°C).

Prepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany